drugset
Drugs / ABH001
last change Nov 2013 re-read 3 minutes ago

ABH001

Cell therapy

Developed for
epidermolysis bullosa
Investigated by
Shire Regenerative Medicine, Inc.

Trials 1

today NCT01749306 · Ph 3
201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT01749306 Dec 2012 → Nov 2013 epidermolysis bullosa Shire Regenerative Medicine, Inc. Terminated No outcome recorded

Press releases naming this drug 1 release

DateIssuerRelease
2013-02-08 Takeda Shire Regenerative Medicine Initiates Phase 3 Study Of ABH001 For Patients With Epidermolysis Bullosa takeda.com ↗

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as ABH001 ClinicalTrials.gov intervention name — accepted as the source's own label NCT01749306 ↗
Modality Cell therapy “Allogenic Neonatal Dermal Fibroblasts Seeded on poly(glycolide-co-L-lactide) (PGLLA) Scaffold” NCT01749306 ↗
Route Topical “ABH001 applications topically every 4 weeks (±1 week) with protocol-specified dressings until wound healed or up to 44 weeks” NCT01749306 ↗